E. Ohman J or Asset Management AB Trims Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

E. Ohman J or Asset Management AB lessened its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 15.4% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 25,284 shares of the medical equipment provider's stock after selling 4,589 shares during the period. E. Ohman J or Asset Management AB's holdings in Lantheus were worth $2,775,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Assenagon Asset Management S.A. purchased a new stake in Lantheus in the third quarter worth $1,863,000. Moody Aldrich Partners LLC purchased a new stake in Lantheus in the third quarter worth $4,211,000. Riverwater Partners LLC purchased a new stake in Lantheus in the third quarter worth $580,000. International Assets Investment Management LLC increased its stake in Lantheus by 4,324.9% in the third quarter. International Assets Investment Management LLC now owns 66,948 shares of the medical equipment provider's stock worth $7,348,000 after purchasing an additional 65,435 shares during the period. Finally, Signaturefd LLC increased its stake in Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock worth $35,000 after purchasing an additional 92 shares during the period. Hedge funds and other institutional investors own 99.06% of the company's stock.

Lantheus Stock Up 0.4 %

LNTH stock traded up $0.49 during trading on Friday, reaching $110.30. 411,035 shares of the company traded hands, compared to its average volume of 962,166. Lantheus Holdings, Inc. has a 12 month low of $50.20 and a 12 month high of $126.89. The business has a 50 day simple moving average of $107.32 and a 200 day simple moving average of $92.93. The company has a market capitalization of $7.66 billion, a price-to-earnings ratio of 18.08 and a beta of 0.50. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.41 and a current ratio of 4.68.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing the consensus estimate of $1.68 by ($0.07). The business had revenue of $394.10 million during the quarter, compared to analyst estimates of $382.12 million. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. Lantheus's revenue was up 22.5% compared to the same quarter last year. During the same period in the prior year, the business posted $1.40 EPS. On average, equities research analysts anticipate that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. B. Riley increased their target price on Lantheus from $105.00 to $146.00 and gave the stock a "buy" rating in a research note on Thursday, July 25th. JMP Securities dropped their price target on Lantheus from $130.00 to $125.00 and set a "market outperform" rating on the stock in a research report on Thursday, August 1st. Truist Financial dropped their price target on Lantheus from $141.00 to $135.00 and set a "buy" rating on the stock in a research report on Thursday, August 1st. Leerink Partners increased their price target on Lantheus from $106.00 to $127.00 and gave the stock an "outperform" rating in a research report on Thursday, July 11th. Finally, Redburn Atlantic assumed coverage on Lantheus in a research report on Tuesday, September 3rd. They set a "buy" rating and a $175.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $126.00.

Insiders Place Their Bets

In other Lantheus news, Director Gerard Ber sold 15,500 shares of the firm's stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the sale, the director now owns 21,221 shares of the company's stock, valued at approximately $2,047,402.08. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Mary Anne Heino sold 10,481 shares of the firm's stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $95.50, for a total value of $1,000,935.50. Following the completion of the transaction, the director now directly owns 454,923 shares in the company, valued at $43,445,146.50. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Gerard Ber sold 15,500 shares of the firm's stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the transaction, the director now owns 21,221 shares of the company's stock, valued at approximately $2,047,402.08. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 27,981 shares of company stock valued at $2,689,156. 1.50% of the stock is currently owned by corporate insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.